Pharmafile Logo
Pharmafocus logo
Advanced Search

breast cancer

Showing 15 posts of 170 posts found.

rocherooflr

NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

October 3, 2019
Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq

NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …

News
roche__tree

Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer

October 1, 2019
Manufacturing and Production, Research and Development Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq

Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical …

News
shutterstock

Age affects efficacy of immunotherapy treatments in breast cancer patients

September 9, 2019
Research and Development, Sales and Marketing Cancer, breast cancer, pharma

Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …

News
roche__tree

Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer

August 30, 2019
Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq

Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …

News

NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer

August 7, 2019
Research and Development, Sales and Marketing Cancer, NCIE, NHS, Nerlynx, Pierre Fabre, UK, breast cancer

Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human …

News
novartis_outside_1

Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer

August 1, 2019
Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma

New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in …

News
lilly_entrance_web

Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data

July 31, 2019
Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma

Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …

News
merck-keytruda

MSD’s Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer

July 30, 2019
Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma

MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when combined …

News

NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer

July 17, 2019
Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma

Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …

News

Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation

July 11, 2019
Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma

Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after …

News

Roche’s Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer

July 2, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Roche, breast cancer, pharma, tecentriq

Roche’s immunotherapy Tecentriq (atezolizumab) has been recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in combination …

News

Pfizer’s Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations

June 24, 2019
Sales and Marketing Pfizer, breast cancer, oncology, pharma

Pfizer’s oral poly (ADP-ribose) polymerase (PARP) inhibitor Talzenna (talazoparib) has secured approval in Europe from the European Commission, the drugmaker …

News

Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer

June 3, 2019
Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma

Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …

News
novartis_side_building

FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer

May 28, 2019
Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma

Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …

News
lilly_entrance_web

Japan’s health ministry warns of serious side effects of Lilly’s Verzenio

May 23, 2019
Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma

Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024